These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2121038)

  • 1. Complications of tissue plasminogen activator therapy after vitrectomy for diabetes.
    Dabbs CK; Aaberg TM; Aguilar HE; Sternberg P; Meredith TA; Ward AR
    Am J Ophthalmol; 1990 Oct; 110(4):354-60. PubMed ID: 2121038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of postvitrectomy fibrin pupillary block with tissue plasminogen activator.
    Jaffe GJ; Lewis H; Han DP; Williams GA; Abrams GW
    Am J Ophthalmol; 1989 Aug; 108(2):170-5. PubMed ID: 2502924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of intraocular fibrin formation with tissue plasminogen activator after vitrectomy].
    Zhao P; Wang W
    Zhonghua Yan Ke Za Zhi; 1995 Jul; 31(4):255-8. PubMed ID: 8745515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue plasminogen activator for postvitrectomy fibrin formation.
    Jaffe GJ; Abrams GW; Williams GA; Han DP
    Ophthalmology; 1990 Feb; 97(2):184-9. PubMed ID: 2109297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transconjunctival 25-gauge sutureless vitrectomy and silicone oil injection in diabetic tractional retinal detachment.
    Altan T; Acar N; Kapran Z; Unver YB; Ozdogan S
    Retina; 2008 Oct; 28(9):1201-6. PubMed ID: 18728620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of tissue plasminogen activator on retinal bleeding.
    Sternberg P; Aguilar HE; Drews C; Aaberg TM
    Arch Ophthalmol; 1990 May; 108(5):720-2. PubMed ID: 2110447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator.
    Williams GA; Lambrou FH; Jaffe GA; Snyder RW; Green GD; Devenyi RG; Abrams GW
    Arch Ophthalmol; 1988 Aug; 106(8):1055-8. PubMed ID: 3135790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal recombinant tPA before vitrectomy for diabetic tractional retinal detachment: A randomized controlled trial.
    Falavarjani KG; Anvari P; Shad E; Dehghan Niri MH; Sedaghat A; Abdi F; Parvaresh MM; Saeidian B; Gordiz A; Amirfarhangi Anbardan A
    Eur J Ophthalmol; 2022 Nov; 32(6):3522-3526. PubMed ID: 35861974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The lowest effective dose of tissue plasminogen activator for fibrinolysis of postvitrectomy fibrin.
    Boldt HC; Abrams GW; Murray TG; Han DP; Mieler WF
    Retina; 1992; 12(3 Suppl):S75-9. PubMed ID: 1455089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results of vitrectomy without endotamponade in proliferative diabetic retinopathy with tractional retinal detachment.
    Tao Y; Jiang YR; Li XX; Gao L; Jonas JB
    Retina; 2010 Mar; 30(3):447-51. PubMed ID: 20216292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tissue plasminogen activator treatment of postvitrectomy pupillary fibrin membrane].
    Maeno T; Maeda N; Ikeda T; Tano Y
    Nippon Ganka Gakkai Zasshi; 1991 Nov; 95(11):1124-8. PubMed ID: 1759654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Vitrectomy and proliferative diabetic retinopathy. Apropos of 66 eyes].
    Bouchard O; Zech JC; Trepsat C
    J Fr Ophtalmol; 1997; 20(4):263-70. PubMed ID: 9181137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of intravitreal recombinant tissue plasminogen activator injection on diabetic tractional fibrovascular membranes: Proposed criteria using optical coherence tomography.
    Ghasemi Falavarjani K; Anvari P; Dehghan Niri M; Molaei S; Abdi F; Shad E; Kazemi P; Sadda SR
    Eur J Ophthalmol; 2022 Jan; 32(1):424-428. PubMed ID: 33653173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Different outcome among eyes with proliferative diabetic retinopathy indicated for vitrectomy].
    Muramatsu M; Yokoi M; Muramatsu A; Saito W; Furudate N; Ohno S
    Nippon Ganka Gakkai Zasshi; 2006 Dec; 110(12):950-60. PubMed ID: 17228758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-silicone oil injection of methotrexate at the end of vitrectomy for advanced proliferative diabetic retinopathy.
    Ghasemi Falavarjani K; Modarres M; Hadavandkhani A; Karimi Moghaddam A
    Eye (Lond); 2015 Sep; 29(9):1199-203. PubMed ID: 26160528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vitreous hemorrhage after vitrectomy in diabetic retinopathy and tissue plasminogen activator].
    Asensio Sánchez VM; Pérez Flández FJ; Carlos Bejarano J; Fernández Concellón L
    Arch Soc Esp Oftalmol; 2002 Jan; 77(1):7-12. PubMed ID: 11813114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal tissue plasminogen activator treatment of experimental vitreous hemorrhage.
    Johnson RN; Olsen KR; Hernandez E
    Arch Ophthalmol; 1989 Jun; 107(6):891-4. PubMed ID: 2499298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical use of recombinant plasminogen activator for intraocular fibrinolysis.
    Koerner F; Boehnke M
    Ger J Ophthalmol; 1992; 1(5):354-60. PubMed ID: 1477641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined 23-gauge sutureless vitrectomy and clear corneal phacoemulsification in patients with proliferative diabetic retinopathy.
    Lee DY; Jeong HS; Sohn HJ; Nam DH
    Retina; 2011 Oct; 31(9):1753-8. PubMed ID: 21555968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of sutureless 25-G+ pars-plana vitrectomy for the management of diabetic tractional retinal detachment.
    Mikhail M; Ali-Ridha A; Chorfi S; Kapusta MA
    Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):255-261. PubMed ID: 27480177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.